Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
about
Thrombotic microangiopathy with targeted cancer agentsCancer-associated thrombotic microangiopathyCurrent and emerging treatment options for hairy cell leukemiaToxin-based therapeutic approachesMonoclonal antibodies in acute lymphoblastic leukemiaFusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivoChemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirsA bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancerAnti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trialImmunotherapy of childhood cancer: from biologic understanding to clinical application.Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapyThe novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.Update on the biology and treatment options for hairy cell leukemia.Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Engineering toxin-resistant therapeutic stem cells to treat brain tumorsConvergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moietiesImpact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.Evidence of canonical somatic hypermutation in hairy cell leukemiaPentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancerAntibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxTreatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.Targeting malignant B cells with an immunotoxin against ROR1Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.Pseudomonas exotoxin kills Drosophila S2 cells via apoptosisA Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor CellsImmunoconjugates in the management of hairy cell leukemia.Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaBispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.
P2860
Q24635904-B7BBCAD8-10AB-4A18-905E-2C6C0022F128Q26738984-2A9D325B-9699-4F74-B5FF-9948B04C79F7Q26796423-BC31D368-601A-42C1-A4C3-B0D6696B1BEDQ27013664-BB7652A6-209F-44A0-A65E-88EB37DE3D6FQ27022540-353CF51D-7A6E-47B6-9F95-32E9058E3840Q27314650-2AAEC5F0-7482-4274-8BBE-47CAD11392A9Q28553712-02455269-B342-4DD2-8457-B0D921E884D5Q33410756-17501C2F-48E8-43A2-BCB7-20959BEC231CQ33415933-847210AC-B2C2-4684-A7F7-0B3CC1647C55Q33604776-E44AB769-A0A2-45CB-91DB-DE42BA108B6FQ33689021-75EBCF29-FC40-4939-B4DA-8CB504F09065Q33732575-92C20696-B674-41F9-836A-7FC3B226EEAEQ33752982-B63E429E-FDE0-440B-A861-668D6A902108Q33779122-3686C555-4F5F-4FE3-9916-07DDB6767CC2Q33840201-37730CF9-4C4F-4CB2-BD6F-22C23EA83036Q33932779-55CC9F0F-60F8-41A4-A2E0-2284A4C5F8B8Q34276680-AAD9E834-AD21-4C5D-9C3D-C441C6E723B6Q34343369-31FF5055-3A10-4C91-9AFE-C91ECC631738Q34387911-D305D804-B455-4D54-B121-FE5D444AE6ADQ34444939-AB3C1545-1B80-46FC-8C33-0ACE93AD6D49Q34575951-AC79AB40-24FE-4868-BA0A-1DCF18ACA846Q34619308-7DC728C4-4FE6-41AD-8FB9-5F37EB5B2C8CQ34804520-B3837C77-492C-4C7A-ADD0-31C357C9AA1BQ34993336-C44330B5-272B-432C-8A5C-B7E630AECF95Q35001615-08C256DC-A33D-4F1B-90A9-6BDF8C8974F5Q35023967-73D65464-45B0-4A9E-BFFB-EF0CD8D4CA7BQ35230663-4A2C6F1D-2313-4F72-B6F9-51DBA25A6BDCQ35317540-140EB9C0-5C3E-4A90-907F-364B2425320EQ35446035-CC73652E-A9D8-4261-8549-494FBFE28F23Q35446333-6EAADD1B-F510-4E21-A3A1-9600CD71ADDBQ35653164-D7DD3B74-A62D-4974-A988-3AA9A97D0412Q35935802-54191F33-F02F-476F-82C6-DED5E50D025AQ35969887-56902AD9-55C9-40CD-A071-3D66EEEA36A6Q36058502-206932C4-8B8F-4E45-B54B-6C0FA92B381EQ36073562-5EF51A78-C749-47C6-A290-4AC00D2FFFFDQ36200380-84F85FA4-6D77-4733-BFEF-E094F711BB8EQ36269852-CF56B719-19BE-4644-A356-13122DB341F7Q36328016-D5B66E54-5D8D-4808-8EFC-CCAD5D72ED1CQ36339717-78DE2877-79BC-457D-BD6D-2A2C070CE049Q36346628-E04BE674-2783-47DF-B280-FCFEA10D9FF7
P2860
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II trial of recombinant immunotoxin RFB4
@nl
Phase II trial of recombinant ...... ents with hairy cell leukemia.
@en
type
label
Phase II trial of recombinant immunotoxin RFB4
@nl
Phase II trial of recombinant ...... ents with hairy cell leukemia.
@en
prefLabel
Phase II trial of recombinant immunotoxin RFB4
@nl
Phase II trial of recombinant ...... ents with hairy cell leukemia.
@en
P2093
P2860
P356
P1476
Phase II trial of recombinant ...... ents with hairy cell leukemia.
@en
P2093
David J P Fitzgerald
Inger Margulies
Ira Pastan
Maryalice Stetler-Stevenson
Pierre Noel
Robert J Kreitman
Wyndham H Wilson
P2860
P304
P356
10.1200/JCO.2008.20.2630
P407
P577
2009-05-04T00:00:00Z